Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda

Eric RogierComments to Author , Jessica N. McCaffery, Doug Nace, Samaly Souza Svigel, Ashenafi Assefa, Jimee Hwang, Simon Kariuki, Aaron M. Samuels, Nelli Westercamp, Arsène Ratsimbasoa, Milijaona Randrianarivelojosia, Aline Uwimana, Venkatachalam Udhayakumar, and Eric S. Halsey
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Rogier, J.N. McCaffery, D. Nace, S.S. Svigel, A.M. Samuels, N. Westercamp, V. Udhayakumar); Ethiopia Public Health Institute, Addis Ababa, Ethiopia (A. Assefa); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Hwang, E.S. Halsey); Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya (S. Kariuki); Centers for Disease Control and Prevention, Kisumu (A.M. Samuels); Madagascar National Malaria Control Program, Antananarivo, Madagascar (A. Ratsimbasoa); Institut Pasteur de Madagascar, Antananarivo (M. Randrianarivelojosia); Université de Toliara, Toliara, Madagascar (M. Randrianarivelojosia); Rwanda Biomedical Center, Kigali, Rwanda (A. Uwimana)

Main Article

Figure 1

Location of TES sites where Plasmodium falciparum malaria-infected participants were enrolled, Ethopia, Kenya, Madagascar, and Rwanda, 2016–2018. A) Ethiopia, B) Kenya, C) Madagascar, D) Rwanda. Circles indciate study sites and diamonds the country capitals. Scale bars are unique to each map. TES, therapeutic efficacy study.

Figure 1. Location of TES sites where Plasmodium falciparum malaria-infected participants were enrolled, Ethopia, Kenya, Madagascar, and Rwanda, 2016–2018. A) Ethiopia, B) Kenya, C) Madagascar, D) Rwanda. Circles indciate study sites and diamonds the country capitals. Scale bars are unique to each map. TES, therapeutic efficacy study.

Main Article

Page created: January 12, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external